NextImmune
Basel
About NextImmune
NextImmune focuses on the research and development of a new generation of immunosuppressive drugs for autoimmune diseases and Organ Transplantation - with objectives of high efficacy and good safety without adverse effects as known from conventional immunosuppressants.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Total funding: $156.8K
- Last round: Grant (Jun 2022)
- Website: nextimmune.com
Industries & Categories
Biotechnology, Health Care
Canonical: https://fsome.com/organization/nextimmune-2232665 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.